TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 10, 2012, Pages 1706-1715

  Zonneveld Huijssoon, Evelien ^a   Van Wijk, Femke ^a   Roord, Sarah ^a   Delemarre, Eveline ^a   Meerding, Jenny ^a   De Jager, Wilco ^a   Klein, Mark ^a   Raz, Eyal ^b   Albani, Salvatore ^c,d   Kuis, Wietse ^a   Boes, Marianne ^a   Prakken, Berent J ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c BURNHAM INSTITUTE   (United States)

^d EUREKA Institute for Translational Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CPG 1668; GAMMA INTERFERON; HEAT SHOCK PROTEIN 60 PEPTIDE VACCINE; INTERLEUKIN 10; PEPTIDE VACCINE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; BYSTANDER EFFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; IMMUNOLOGICAL TOLERANCE; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 85027937949     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201131     Document Type: Article

References (81)

1. Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005;366:50-6.
2. Hafler DA, Kent SC, Pietrusewicz MJ, et al. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann NY Acad Sci 1997;835:120-31.
3. Prakken BJ, Wendling U, van der Zee R, et al. Induction of IL-10 and inhibition of experimental arthritis are specific features of microbial heat shock proteins that are absent for other evolutionarily conserved immunodominant proteins. J Immunol 2001;167:4147-53.
4. Anderton SM, van der Zee R, Prakken B, et al. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J Exp Med 1995;181:943-52.
5. Chu CQ, Londei M. Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. J Autoimmun 1999;12:35-42.
6. Larché M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005;11(4 Suppl):S69-76.
7. Brownlie RJ, Myers LK, Wooley PH, et al. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum 2006;54:854-63.
8. Zonneveld-Huijssoon E, Roord ST, de Jager W, et al. Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide. Ann Rheum Dis 2011;70:2199-206.
9. Huurman VA, Decochez K, Mathieu C, et al. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007;23:269-75.
10. Koffeman EC, Genovese M, Amox D, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum 2009;60:3207-16.
11. Corrigall VM, Bodman-Smith MD, Brunst M, et al. Inhibition of antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an antiinflammatory cytokine profile by the stress protein BiP: relevance to the treatment of inflammatory arthritis. Arthritis Rheum 2004;50:1164-71.
12. Huurman VA, van der Meide PE, Duinkerken G, et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008;152:488-97.
13. Thurau SR, Fricke H, Burchardi C, et al. Long-term follow-up of oral tolerance induction with HLA-peptide B27PD in patients with uveitis. Ann NY Acad Sci 2004;1029:408-12.
14. Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 2008;58:3873-83.
15. Holmgren J, Czerkinsky C, Eriksson K, et al. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003;21 (Suppl 2):S89-95.
16. Moschos SA, Bramwell VW, Somavarapu S, et al. Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 2004;82:628-37.
17. Decrausaz L, Domingos-Pereira S, Duc M, et al. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer 2011;129:762-72.
18. Bouvet JP, Decroix N, Pamonsinlapatham P. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol 2002;23:209-13.
19. Dietrich G, Griot-Wenk M, Metcalfe IC, et al. Experience with registered mucosal vaccines. Vaccine 2003;21:678-83.
20. Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-Dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006;193:598-600.
21. Ichinohe T, Ainai A, Tashiro M, et al. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009;27:6276-9.
22. Ivory CP, Chadee K. Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge. Infect Immun 2007;75:4917-22.
23. Mariotti S, Teloni R, von Hunolstein C, et al. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine 2002;20:2229-39.
24. Holmgren J, Adamsson J, Anjuère F, et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005;97:181-8.
25. Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010;34:408-15.
26. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003;9:831-5.
27. Lenert P. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol 2005;140:1-10.
28. Mangsbo SM, Sandin LC, Anger K, et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010;33:225-35.
29. Liang X, Moseman EA, Farrar MA, et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010;115:5041-52.
30. Nierkens S, den Brok MH, Roelofsen T, et al. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS ONE 2009;4:e8368.
31. Westwood JA, Haynes NM, Sharkey J, et al. Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice. Clin Cancer Res 2009;15:7624-33.
32. De Cesare M, Sfondrini L, Campiglio M, et al. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother 2010;33:8-15.
33. Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22:3136-43.
34. Bhat AA, Seth RK, Kumar S, et al. Induction of cell-mediated immune responses to peptide antigens of P. vivax in microparticles using intranasal immunization. Immunol Invest 2010;39:483-99.
35. Søgaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010;51:42-50.
36. Birnbaum G, Kotilinek L, Miller SD, et al. Heat shock proteins and experimental autoimmune encephalomyelitis. II: Environmental infection and extra-neuraxial inflammation alter the course of chronic relapsing encephalomyelitis. J Neuroimmunol 1998;90:149-61.
37. Feleszko W, Jaworska J, Hamelmann E. Toll-like receptors - novel targets in allergic airway disease (probiotics, friends and relatives). Eur J Pharmacol 2006;533:308-18.
38. Okada H, Kuhn C, Feillet H, et al. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010;160:1-9.
39. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
40. Boccaccio GL, Mor F, Steinman L. Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis. Int Immunol 1999;11:289-96.
41. Gilkeson GS, Ruiz P, Pippen AM, et al. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J Exp Med 1996;183:1389-97.
42. Chervonsky AV. Influence of microbial environment on autoimmunity. Nat Immunol 2010;11:28-35.
43. Arnold IC, Dehzad N, Reuter S, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 2011;121:3088-93.
44. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010;330:1768-73.
45. Marta M, Andersson A, Isaksson M, et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008;38:565-75.
46. Fallarino F, Volpi C, Zelante T, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol 2009;183:6303-12.
47. Quintana FJ, Rotem A, Carmi P, et al. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 2000;165:6148-55.
48. Meyers JA, Mangini AJ, Nagai T, et al. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine 2006;35:235-46.
49. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 2005;5:318-30.
50. Prakken BJ, van der Zee R, Anderton SM, et al. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci U S A 1997;94:3284-9.
51. Prakken BJ, van der Zee R, Anderton SM, et al. Tolerance to an arthritogenic T-cell epitope of HSP65 and the regulation of experimental arthritis. Ann NY Acad Sci 1996;778:425-6.
52. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977;146:857-68.
53. Hubert FX, Voisine C, Louvet C, et al. Differential pattern recognition receptor expression but stereotyped responsiveness in rat spleen dendritic cell subsets. J Immunol 2006;177:1007-16.
54. de Jager W, Prakken B, Rijkers GT. Cytokine multiplex immunoassay: methodology and (clinical) applications. Methods Mol Biol 2009;514:119-33.
55. Obermeier F , Strauch UG, Dunger N, et al . In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 2005;54:1428-36.
56. Bleich A, Janus LM, Smoczek A, et al. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. Gastroenterology 2009;136:278-87.
57. Jain VV, Kitagaki K, Businga T, et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol 2002;110:867-72.
58. Ouabed A, Hubert FX, Chabannes D, et al. Differential control of T regulatory cell proliferation and suppressive activity by mature plasmacytoid versus conventional spleen dendritic cells. J Immunol 2008;180:5862-70.
59. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005;206:232-59.
60. Thurau SR, Diedrichs-Möhring M, Fricke H, et al. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett 1999;68:205-12.
61. Chiaramonte MG, Hesse M, Cheever AW, et al. CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. J Immunol 2000;164:973-85.
62. Mühl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferongamma. Int Immunopharmacol 2003;3:1247-55.
63. Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol 2008;29:479-86.
64. Kim EY, Moudgil KD. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol Lett 2008;120:1-5.
65. Hayashi T, Beck L, Rossetto C, et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004;114:270-9.
66. Sarkar SA, Wong R, Hackl SI, et al. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes 2007;56:72-9.
67. Hill M, Tanguy-Royer S, Royer P, et al. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 2007;37:3054-62.
68. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4:1206-12.
69. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
70. Bilsborough J, George TC, Norment A, et al. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 2003;108:481-92.
71. de Jong H, Lafeber FF, de Jager W, et al. Pan-DR-binding Hsp60 self epitopes induce an interleukin-10-mediated immune response in rheumatoid arthritis. Arthritis Rheum 2009;60:1966-76.
72. Hori S, Haury M, Coutinho A, et al. Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci U S A 2002;99:8213-8.
73. Nishimura E, Sakihama T, Setoguchi R, et al. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol 2004;16:1189-201.
74. Tarbell KV, Yamazaki S, Olson K, et al. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004;199:1467-77.
75. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455-65.
76. Elst EF, Klein M, de Jager W, et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008;58:547-55.
77. Quintana FJ, Mimran A, Carmi P, et al. HSP60 as a target of anti-ergotypic regulatory T cells. PLoS ONE 2008;3:e4026.
78. Wang X, Zhou S, Chi Y, et al. CD4+CD25+ Treg induction by an HSP60-derived peptide SJMHE1 from Schistosoma japonicum is TLR2 dependent. Eur J Immunol 2009;39:3052-65.
79. Zanin-Zhorov A, Cahalon L, Tal G, et al. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006;116:2022-32.
80. Massa M, Passalia M, Manzoni SM, et al. Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1648-57.
81. Moseman EA, Liang X, Dawson AJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004;173:4433-42.